Feng Yimei, Li Xiaoping, Cassady Kaniel, Zou Zhongmin, Zhang Xi
Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, Chongqing, China.
Front Oncol. 2019 Apr 2;9:210. doi: 10.3389/fonc.2019.00210. eCollection 2019.
Over the last decade, investigation of () gene function and mutation have become of increasing interest in the field of hematology. This heightened interest was sparked by the seminal discoveries that (1) mutation is associated with development of hematological malignancies and that (2) the TET family of proteins is critical in promoting DNA demethylation and immune homeostasis. Since then, additional studies have begun to unravel the question "Does TET2 have additional biological functions in the regulation of hematopoiesis?" Here, we present a mini-review focused on the current understanding of TET2 in hematopoiesis, hematological malignancies, and immune regulation. Importantly, we highlight the critical function that TET2 facilitates in maintaining the stability of the genome. Based on our review of the literature, we provide a new hypothesis that loss of TET2 may lead to dysregulation of the DNA repair response, augment genome instability, and subsequently sensitize myeloid leukemia cells to PARP inhibitor treatment.
在过去十年中,对()基因功能和突变的研究在血液学领域越来越受到关注。这种兴趣的增加是由一些开创性的发现引发的,即(1)突变与血液系统恶性肿瘤的发生有关,以及(2)TET蛋白家族在促进DNA去甲基化和免疫稳态方面至关重要。从那时起,更多的研究开始探讨“TET2在造血调控中是否具有其他生物学功能?”这一问题。在此,我们进行一项小型综述,重点关注目前对TET2在造血、血液系统恶性肿瘤和免疫调节方面的理解。重要的是,我们强调了TET2在维持基因组稳定性方面所发挥的关键作用。基于我们对文献的综述,我们提出了一个新的假说,即TET2的缺失可能导致DNA修复反应失调,增加基因组不稳定性,并随后使髓系白血病细胞对PARP抑制剂治疗敏感。